Vivani Medical plans a Q4 2024 clinical study in Australia for its mini GLP-1 obesity implant, comparing it to Bydureon BCise and semaglutide.

Vivani Medical plans to initiate its first clinical study for its NPM-115 program, a mini GLP-1 obesity implant, in Australia's Q4 2024. The LIBERATE-1 study will compare the implant's safety, tolerability, and pharmacokinetic profile to weekly injections of Bydureon BCise and semaglutide. The data from the exenatide implant supports its development program and obesity portfolio.